List of Excipients in Branded Drug MOZOBIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	MOZOBIL	plerixafor	0024-5862	HYDROCHLORIC ACID
Sanofi-Aventis US LLC	MOZOBIL	plerixafor	0024-5862	SODIUM CHLORIDE
Sanofi-Aventis US LLC	MOZOBIL	plerixafor	0024-5862	SODIUM HYDROXIDE
Sanofi-Aventis US LLC	MOZOBIL	plerixafor	0024-5862	WATER

Mozobil Excipient Strategy and Commercial Opportunities for Plerixafor

Last updated: September 24, 2026

Mozobil is an injectable plerixafor product used with granulocyte-colony stimulating factor, or G-CSF, to mobilize hematopoietic stem cells before autologous transplantation. Its commercial opportunity is primarily in generic or regional injectable supply, hospital procurement, contract manufacturing, and differentiated presentation formats rather than in novel excipient claims. The reference formulation is chemically simple: plerixafor in an aqueous, isotonic solution containing sodium chloride, with pH adjustment using hydrochloric acid and sodium hydroxide. The main development risks are sterile manufacturing, container-closure compatibility, extractables and leachables, stability, and regulatory equivalence. (FDA, 2008)

What is Mozobil and what excipients does it contain?

Mozobil contains plerixafor, also known as AMD3100, at a concentration of 20 mg/mL. The U.S. reference product is supplied as a sterile solution in a single-dose vial containing 1.2 mL, equivalent to 24 mg of plerixafor. The labeled administration is subcutaneous injection. (FDA, 2008)

Product characteristic	Reference-product profile
Brand	Mozobil
Active ingredient	Plerixafor
Strength	20 mg/mL
Commercial vial	1.2 mL single-dose vial
Route	Subcutaneous injection
Primary use	Stem-cell mobilization before autologous transplantation
Main co-therapy	G-CSF
Core excipients	Sodium chloride, water for injection, hydrochloric acid and sodium hydroxide for pH adjustment
Preservative	None identified in the U.S. reference formulation
Dosage form	Sterile injectable solution

The formulation is designed for immediate parenteral administration rather than long-term storage after opening. The absence of a preservative supports a single-dose presentation and reduces preservative-related tolerability and compatibility issues.

What is the function of each Mozobil excipient?

Excipient	Formulation role	Commercial relevance
Sodium chloride	Provides isotonicity and supports injection tolerability	Low-cost, low-risk, widely available
Water for injection	Solvent	Requires validated pharmaceutical-grade water system
Hydrochloric acid	pH adjustment	Controls product pH and may affect stability
Sodium hydroxide	pH adjustment	Used to achieve the target pH during manufacture

Plerixafor is a small-molecule, water-soluble compound. The simple formulation reduces the need for solubilizers, surfactants, complexing agents, antioxidants or viscosity modifiers. That simplicity limits the scope for excipient-based differentiation but reduces development and manufacturing complexity.

What formulation patents protect Mozobil?

The commercial protection for Mozobil has historically centered on plerixafor composition, use and formulation rights rather than on a complex excipient platform. The product does not depend on a sustained-release system, device-specific delivery technology or proprietary excipient combination.

Publicly available FDA materials identify the product, active ingredient, dosage form and regulatory history, but FDA labeling does not establish a current, enforceable patent position for every global market. Patent rights must be assessed jurisdiction by jurisdiction through national patent registers, Orange Book records and litigation databases. (FDA, 2008; FDA, 2024a)

Are the Mozobil excipients likely to support new patent claims?

The standard excipient combination is unlikely to generate strong composition-of-matter protection because:

1. Sodium chloride in an aqueous injectable product is conventional.
2. Hydrochloric acid and sodium hydroxide are standard pH-adjusting agents.
3. Water for injection is a compendial pharmaceutical vehicle.
4. The formulation does not appear to rely on an unusual stabilizer, buffer system or delivery matrix.

Potentially patentable improvements could involve:

• A defined pH range that improves plerixafor stability.
• Reduced degradation during long-term refrigerated storage.
• A low-extractables vial or prefilled syringe.
• A ready-to-use presentation with reduced preparation time.
• A concentrated formulation that reduces injection volume.
• A lyophilized formulation with improved shelf life.
• A container-closure system that minimizes adsorption or leachables.
• A formulation compatible with autoinjector or wearable delivery.
• A new salt, polymorph or solid-state form of plerixafor.
• A manufacturing process that reduces impurities or improves yield.

These claims would require comparative stability data, impurity profiling, container-closure studies and a credible technical advantage over the reference formulation.

When does Mozobil lose exclusivity?

Mozobil received U.S. approval in December 2008. Its regulatory exclusivity periods have expired. The original product also has a mature small-molecule patent profile, so current commercial barriers are more likely to arise from injectable development, regulatory approval, supply reliability and institutional contracting than from basic FDA exclusivity. (FDA, 2008; FDA, 2024a)

Exclusivity category	Mozobil position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Expired
Pediatric exclusivity	No current commercial effect
Small-molecule patent protection	Mature or expired for core historical rights in major markets
Biosimilar exclusivity	Not applicable
Generic pathway	Abbreviated new drug application, subject to applicable regulatory requirements

Plerixafor is not a biologic. Biosimilar competition is therefore not the relevant pathway. Competition would normally arise through generic or hybrid injectable products, depending on the jurisdiction and the proposed formulation.

What is the FDA regulatory status of Mozobil?

The FDA approved Mozobil for use with G-CSF to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. The product is administered by subcutaneous injection, generally approximately 11 hours before apheresis, according to the prescribing information. (FDA, 2008)

The regulatory reference points for a competing product include:

• Identity and strength of plerixafor.
• Sterility and endotoxin control.
• Subcutaneous injectable performance.
• Assay and related-substance specifications.
• Stability under proposed storage conditions.
• Container-closure integrity.
• Particulate matter and visible inspection.
• Extractables and leachables.
• Comparability of excipients and concentrations.
• Labeling for the same patient population and clinical use.

A product using the same qualitative and quantitative excipient profile has a simpler regulatory narrative than a product using novel excipients or a materially different formulation. A materially different formulation may trigger additional comparative studies, formulation bridging or a more complex regulatory pathway.

What excipient strategy is most attractive for a Mozobil generic?

The strongest initial strategy is a reference-matched formulation with limited excipient variation. This approach reduces regulatory risk and supports a direct substitution proposition for hospitals and transplant centers.

Strategy 1: Reference-matched solution

A generic manufacturer can reproduce the core formulation using:

• Plerixafor at 20 mg/mL.
• Sodium chloride for isotonicity.
• Water for injection.
• Hydrochloric acid and sodium hydroxide for pH adjustment.
• A single-dose sterile vial.

This approach has the lowest formulation risk. The principal development work shifts to analytical method validation, impurity control, sterile filling and packaging.

Strategy 2: Improved container-closure system

The most commercially credible differentiation may come from packaging rather than excipient composition. Opportunities include:

• Low-binding glass vial systems.
• Improved stopper coatings.
• Low-particulate elastomeric closures.
• Reduced overfill.
• Tamper-evident packaging.
• Unit-dose cartons with barcode and traceability features.
• Ready-to-use presentations for transplant centers.

A packaging improvement can reduce product waste and preparation time without changing the injectable formulation. The commercial value is strongest where pharmacy workflow and hospital acquisition costs are material.

Strategy 3: Prefilled syringe

A prefilled syringe could reduce vial transfer steps and preparation errors. It would require assessment of:

• Syringe material compatibility.
• Silicone oil and tungsten residues.
• Plunger extractables.
• Protein or small-molecule adsorption, although plerixafor is not a protein.
• Needle safety.
• Delivered-volume accuracy.
• Human-factors considerations.
• Stability throughout the labeled shelf life.

The regulatory and manufacturing burden would be higher than for a vial. The opportunity depends on whether transplant centers value workflow savings enough to accept a higher acquisition price.

Strategy 4: Reduced-volume or concentrated product

A more concentrated product could lower injection volume, but it would need evidence that the revised formulation remains tolerable by the subcutaneous route. Higher concentration can increase local pain, precipitation risk, viscosity or injection force. This strategy has technical potential but is less attractive as a first generic launch because it creates greater regulatory separation from the reference product.

Strategy 5: Lyophilized formulation

A freeze-dried plerixafor presentation could target improved storage stability or expanded geographic distribution. The commercial case is limited if the reference solution already has acceptable refrigerated stability and hospitals prefer ready-to-use products. Lyophilization also adds reconstitution steps, equipment requirements and opportunities for dosing error.

How strong is the Mozobil formulation patent estate?

The formulation patent estate appears less defensible than estates built around long-acting delivery, lipid nanoparticles, depot injections or proprietary excipient systems. The reference product’s excipients are conventional, and the product does not depend on a complex delivery mechanism.

Patent strength is more likely to arise from a narrow technical improvement than from the basic formulation. The strongest potential claims would require a measurable result, such as:

• A specific impurity reduction.
• A defined shelf-life extension.
• Improved stability at room temperature.
• Reduced subvisible particles.
• Improved syringe compatibility.
• Reduced injection volume with maintained tolerability.
• A manufacturing process that produces a distinctive impurity profile.

Broad claims covering plerixafor, saline and pH adjustment would face substantial prior-art and obviousness challenges. A later entrant should conduct freedom-to-operate analysis for active-ingredient patents, process patents, formulation patents, packaging patents and use claims in each target market.

What is the Orange Book status of Mozobil?

The Orange Book is relevant because Mozobil is an FDA-approved small-molecule drug. It identifies approved products and, where applicable, patent and exclusivity information submitted for listing. The current Orange Book and FDA patent-listing resources should be reviewed for active listed patents, certifications and any approved generic competition. (FDA, 2024a; FDA, 2024b)

A generic applicant may face:

• Paragraph I certification if no relevant patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification if approval is deferred until patent expiration.
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable or not infringed.

For a mature product such as Mozobil, the key risk is less likely to be a new basic composition patent and more likely to be a listed method-of-use or formulation patent, if any remains active. The applicant must also evaluate non-Orange Book rights, including process, manufacturing and packaging patents.

Which companies are challenging Mozobil exclusivity?

Plerixafor competition can come from generic injectable manufacturers, specialty pharmaceutical companies and regional suppliers. The relevant competitive set includes companies with:

• Aseptic filling capacity.
• Commercial experience with hospital injectables.
• Ability to qualify plerixafor API.
• Regulatory infrastructure for ANDA or equivalent filings.
• Distribution into transplant and oncology accounts.
• Capacity to maintain reliable supply during episodic demand surges.

No biosimilar competitor is relevant because plerixafor is a chemically synthesized small molecule. Competitive intensity will depend on the number of approved generic suppliers, the timing of launches and the willingness of group purchasing organizations to switch suppliers.

What generic entry risks exist for Mozobil?

Pricing pressure

A generic injectable launch can reduce net prices quickly if several suppliers enter simultaneously. The effect may be less severe than for high-volume oral drugs because the addressable market is specialized and the product requires sterile manufacturing.

Limited market size

Plerixafor is used in a narrow clinical setting. Demand depends on transplant volume, mobilization protocols and the proportion of patients receiving plerixafor. A small market limits the number of economically viable suppliers.

Manufacturing barriers

Sterile injectable manufacturing is a meaningful barrier. Key requirements include:

• Validated aseptic processing.
• Sterilizing filtration where applicable.
• Media fills.
• Container-closure integrity testing.
• Particulate control.
• Visual inspection.
• Low bioburden water systems.
• Validated cleaning and environmental monitoring.
• Reliable plerixafor API supply.

These barriers can protect margins after basic patent expiry, but they also increase launch cost and supply risk.

Clinical substitution risk

Hospitals may substitute based on acquisition price, availability and contract terms. Transplant centers may prefer suppliers with reliable delivery because treatment schedules are time-sensitive. A low-cost product with inconsistent supply may lose share to a higher-priced supplier with stronger service levels.

What commercial opportunities exist for Mozobil excipients and presentations?

The highest-value opportunities are likely to involve product usability and supply economics rather than novel excipient licensing.

Opportunity	Technical complexity	Commercial potential
Reference-matched vial	Low to moderate	High for generic entry
Improved stopper and vial system	Moderate	Moderate
Prefilled syringe	Moderate to high	Moderate
Room-temperature-stable product	High	Potentially high in international markets
Reduced-volume formulation	High	Moderate
Lyophilized product	High	Selective
Co-packaged G-CSF and plerixafor	Regulatory and operational complexity	Potentially high
Hospital-specific unit-dose packaging	Low to moderate	Moderate
Regional contract manufacturing	Moderate	High where supply is constrained

A co-packaged product could improve treatment coordination because Mozobil is used with G-CSF. It would not necessarily create a new combination product, but the regulatory, labeling and supply-chain implications would need careful review. The commercial advantage would be strongest in markets where transplant centers purchase both products through coordinated protocols.

How does Mozobil compare with competing stem-cell mobilization approaches?

Plerixafor competes with mobilization using G-CSF alone, chemotherapy plus G-CSF and risk-adapted or preemptive plerixafor protocols. Its value is linked to mobilization success, avoidance of collection failure and reduced need for repeat apheresis.

Approach	Product profile	Excipient opportunity	Commercial implication
G-CSF alone	Biologic injectable	Limited for plerixafor suppliers	Lower drug cost but variable mobilization
Chemotherapy plus G-CSF	Multi-agent regimen	Not directly comparable	More complex and patient-specific
Plerixafor plus G-CSF	Small molecule plus biologic	Injectable formulation and packaging	Higher acquisition cost with potential workflow and mobilization benefits
Generic plerixafor	Small-molecule injectable	Reference matching and packaging	Price competition with supply reliability as a differentiator

Plerixafor’s commercial position depends on clinical protocols and payer policy. A generic supplier should target transplant centers, oncology hospitals and group purchasing organizations rather than relying only on broad retail distribution.

What licensing deals are relevant to Mozobil excipient commercialization?

The most relevant licensing structures would cover:

• Plerixafor API supply.
• Sterile fill-finish capacity.
• Prefilled syringe technology.
• Low-extractables container systems.
• Stability-enhancing formulation technology.
• Regional marketing rights.
• Hospital distribution and specialty pharmacy access.

A formulation-license deal is most defensible when it includes data demonstrating a clear advantage over the reference product. Conventional saline and pH-adjustment excipients alone are unlikely to support a significant royalty-bearing platform license.

Key Takeaways

• Mozobil is a 20 mg/mL plerixafor sterile injectable supplied in a single-dose vial.
• The reference formulation uses a simple excipient system: sodium chloride, water for injection and pH adjustment with hydrochloric acid and sodium hydroxide.
• Core FDA and orphan-drug exclusivity periods have expired.
• Biosimilar competition is not relevant because plerixafor is a small molecule.
• A reference-matched generic vial is the lowest-risk commercial strategy.
• Packaging, prefilled syringes, stability and supply reliability offer more realistic differentiation than conventional excipient substitutions.
• The main barriers are aseptic manufacturing, analytical control, container compatibility and hospital contracting.
• Strong new patent claims would likely require demonstrated stability, impurity, delivery or packaging advantages.
• The commercial opportunity is specialized but defensible for manufacturers with reliable sterile injectable capacity.

FAQs

Can a generic Mozobil use different excipients?

Yes. A competing product may use different excipients if it meets applicable quality, safety, stability and equivalence requirements. A reference-matched formulation generally reduces regulatory and development risk.

Is plerixafor a biologic that requires a biosimilar application?

No. Plerixafor is a chemically synthesized small molecule. Competition generally proceeds through generic or equivalent small-molecule regulatory pathways.

Can a preservative be added to a Mozobil formulation?

A preservative could be technically evaluated, but it would alter the reference formulation and may create new tolerability, compatibility, stability and regulatory issues. A preservative-free single-dose product is commercially simpler.

Does a prefilled syringe have stronger patent value than a vial?

Potentially, but patent strength would depend on a specific technical advance, such as improved stability, reduced adsorption, lower extractables or validated delivery performance. The presentation alone is unlikely to support broad protection.

What is the best commercial entry point for a Mozobil competitor?

A reference-matched 20 mg/mL sterile vial supported by dependable supply, competitive hospital pricing and strong quality documentation is the most practical entry point. A prefilled syringe or improved stability product is better positioned as a second-stage differentiation strategy.

References

1. U.S. Food and Drug Administration. (2008). Mozobil (plerixafor) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024b). Approved drug product patents and exclusivity information. FDA.

4. National Library of Medicine. (2024). DailyMed: Mozobil, plerixafor injection. U.S. National Library of Medicine.

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.